Loading...
•
Sep 30
•/
GSK Q3 2025 Earnings Report
GSK delivered strong quarterly growth driven by Specialty Medicines and raised its full-year guidance.
Key Takeaways
GSK reported £8.55 billion in revenue and £2.2 billion in net income for Q3 2025, with EPS per ordinary share estimated at £0.585 after converting from reported ADS values. Specialty Medicines saw double-digit growth while Vaccines and General Medicines remained steady.
Specialty Medicines revenue grew 16% year-over-year, driven by HIV and Oncology.
Free cash flow nearly doubled to £2.5 billion in the quarter.
Raised full-year guidance for sales, EPS, and free cash flow.
New product launches and strong pipeline progress support long-term growth.
GSK
GSK
GSK Revenue by Segment
GSK Revenue by Geographic Location
Revenue by Segment
Specialty Medicines Revenue
CapyFin.comVaccines Revenue
CapyFin.comGeneral Medicines Revenue
CapyFin.comRevenue by Geographic Location
US Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
GSK raised its full-year 2025 guidance based on strong performance in Specialty Medicines and cash generation.
Positive Outlook
- Upgraded full-year sales growth outlook to 9–10%.
- Higher free cash flow expected due to strong operating leverage.
- EPS guidance increased to 17–20% growth.
- Continued momentum in HIV long-acting treatments.
- Pipeline progression with 15 potential launches by 2031.
Challenges Ahead
- General Medicines growth expected to remain flat.
- COVID-19 vaccine revenue tapering off.
- Higher R&D expenses may pressure margins in Q4.
- Foreign exchange headwinds may impact reported results.
- Macroeconomic uncertainties could affect vaccine uptake in international markets.